- Report
- October 2024
- 197 Pages
Global
From €3348EUR$3,545USD£2,848GBP
€3720EUR$3,939USD£3,164GBP
- Report
- May 2024
- 137 Pages
Global
From €6138EUR$6,499USD£5,220GBP
- Report
- July 2024
- 231 Pages
Global
From €7508EUR$7,950USD£6,386GBP
- Report
- May 2022
- 196 Pages
Global
From €2479EUR$2,625USD£2,109GBP
€4958EUR$5,250USD£4,217GBP
- Report
- October 2022
- 270 Pages
Global
From €3541EUR$3,750USD£3,012GBP
- Report
- February 2024
- 250 Pages
Global
From €4722EUR$5,000USD£4,016GBP
- Report
- May 2021
- 50 Pages
China
From €2455EUR$2,600USD£2,088GBP
- Report
- September 2021
- 111 Pages
Global
From €4250EUR$4,500USD£3,615GBP
- Report
- November 2023
- 30 Pages
Global
From €3069EUR$3,250USD£2,611GBP
- Report
- August 2023
- 295 Pages
Global
From €8972EUR$9,500USD£7,631GBP
- Report
- February 2022
- 210 Pages
Global
From €7083EUR$7,500USD£6,024GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2597EUR$2,750USD£2,209GBP
- Report
- April 2022
- 188 Pages
Global
From €3400EUR$3,600USD£2,892GBP
- Report
- September 2020
- 65 Pages
Global
€1245EUR$1,318USD£1,059GBP
- Report
- April 2018
United States
From €7550EUR$7,995USD£6,422GBP
Simponi is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Simponi is administered as an injection or infusion and is available in both brand-name and generic forms.
The Simponi market is a subset of the larger immune disorders drugs market. It is a highly competitive market, with several major players offering similar products. The market is expected to grow in the coming years, driven by increasing prevalence of immune disorders and the introduction of new treatments.
Companies in the Simponi market include Janssen Biotech, Inc., Merck & Co., Inc., Pfizer, Inc., and AbbVie, Inc. Show Less Read more
